Development of an immune evasive stem cell line for type 1 diabetes regenerative therapy
Active Project Grant Awarded Last action
- Award ID
- R41DK142395
- Recipient
-
Aleutian Therapeutics, Inc. UEI E797SLBJB9F1
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $372,067
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 74% complete
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of insulin-producing Β-cells within pancreatic islets, culminating in dysregulated blood glucose levels, affecting 2 million americans. The standard of care for T1DM is continuous glucose monitoring and exogenous insulin therapy. Despite significant advancements in insulin delivery methods, only 17% of children and 21% of adults achieve the recommended HBA1C levels of
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $372,067 |
Quick answers
Who received award R41DK142395?
R41DK142395 was awarded to Aleutian Therapeutics, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 7, 2025.
How much is award R41DK142395 worth?
$372,067 has been obligated on R41DK142395.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award